ORLADEYO Film-coated granules in sachet Ref.[116874] Active ingredients: Berotralstat

Source: European Medicines Agency (EU)  Revision Year: 2026  Publisher: BioCryst Ireland Limited, Block 4, Harcourt Centre, Harcourt Road, DUBLIN 2, D02HW77, Ireland

Product name and form

Orladeyo 72 mg film-coated granules in sachet.

Orladeyo 96 mg film-coated granules in sachet.

Orladeyo 108 mg film-coated granules in sachet.

Orladeyo 132 mg film-coated granules in sachet.

Pharmaceutical Form

Film-coated granules in sachet.

White to off-white, plain-faced, round film-coated granules, approximately 2 mm in diameter.

Qualitative and quantitative composition

Orladeyo 72 mg film-coated granules in sachet: Each sachet contains 72 mg berotralstat (as dihydrochloride).

Orladeyo 96 mg film-coated granules in sachet: Each sachet contains 96 mg berotralstat (as dihydrochloride).

Orladeyo 108 mg film-coated granules in sachet: Each sachet contains 108 mg berotralstat (as dihydrochloride).

Orladeyo 132 mg film-coated granules in sachet: Each sachet contains 132 mg berotralstat (as dihydrochloride).

For the full list of excipients, see section 6.1.

Active Ingredient

Berotralstat is an inhibitor of plasma kallikrein. In patients with hereditary angioedema (HAE) due to C1-INH deficiency or dysfunction, normal regulation of plasma kallikrein activity is impaired, which leads to uncontrolled increases in plasma kallikrein activity and bradykinin release, resulting in HAE attacks consisting of swelling (angioedema).

List of Excipients

Granule core:

Crospovidone (type A)
Magnesium stearate
Silica, colloidal anhydrous
Starch, pregelatinised

Granule coating:

Butylated methacrylate copolymer, basic (E1205)
Sodium laurilsulphate
Silica, colloidal anhydrous
Stearic acid
Talc (E553b)
Titanium dioxide (E171)

Pack sizes and marketing

PET/AL/PE foil laminate sachets.

Pack size: 28 sachets (each carton contains 4 wallets with 7 sachets each).

Marketing authorization holder

BioCryst Ireland Limited, Block 4, Harcourt Centre, Harcourt Road, DUBLIN 2, D02HW77, Ireland

Marketing authorization dates and numbers

EU/1/21/1544/003
EU/1/21/1544/004
EU/1/21/1544/005
EU/1/21/1544/006

Date of first authorisation: 30 April 2021
Date of latest renewal: 12 February 2026

Drugs

Drug Countries
ORLADEYO Austria, Estonia, Spain, France, Croatia, Ireland, Israel, Italy, Japan, Lithuania, Poland

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.